Literature DB >> 27072301

Long-Term Prognosis After Coronary Artery Calcium Scoring Among Low-Intermediate Risk Women and Men.

Anita A Kelkar1, William M Schultz1, Faisal Khosa1, Joshua Schulman-Marcus1, Briain W J O'Hartaigh1, Heidi Gransar1, Michael J Blaha1, Joseph T Knapper1, Daniel S Berman1, Arshed Quyyumi1, Matthew J Budoff1, Tracy Q Callister1, James K Min1, Leslee J Shaw2.   

Abstract

BACKGROUND: Cardiovascular screening of women using traditional risk factors has been challenging, with results often classifying a majority of women as lower risk than men. The aim of this report was to determine the long-term prognosis of asymptomatic women and men classified at low-intermediate risk undergoing screening with coronary artery calcium (CAC) scoring. METHODS AND
RESULTS: A total of 2363 asymptomatic women and men with traditional risk factors aggregating into a low-intermediate Framingham risk score (6%-9.9%; 10-year predicted risk) underwent CAC scanning. Individuals were followed up for a median of 14.6 years. We estimated all-cause mortality using Cox proportional hazards models; hazard ratios with 95% confidence intervals were calculated. The area under the curve from a receiver operating characteristics curve analysis was calculated. There were 1072 women who were older (55.6 years) when compared with the 1291 men (46.7 years; P<0.0001), resulting in a greater prevalence and extent of CAC; 18.8% of women and 15.1% of men had a CAC score ≥100 (P=0.029). This older group of women had a 1.44-fold higher 15-year adjusted mortality hazard when compared with men (P=0.022). For women, the 15-year mortality ranged from 5.0% for those with a CAC score of 0 to 23.5% for those with a CAC score ≥400 (P<0.001). For men, the 15-year mortality ranged from 3.5% for those with a CAC score of 0 to 18.0% for those with a CAC score ≥400 (P<0.001). Women with CAC scores >10 had a higher mortality risk when compared with men.
CONCLUSIONS: Our findings extend previous work that CAC effectively identifies high-risk women with a low-intermediate risk factor burden. These data require validation in external cohorts but lend credence to the use of CAC in women to improve risk detection algorithms that are currently based on traditional risk factors.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  ROC curve; diagnosis; prognosis; proportional hazards models; risk factors

Mesh:

Year:  2016        PMID: 27072301     DOI: 10.1161/CIRCIMAGING.115.003742

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  24 in total

1.  Quantitative myocardial perfusion from static cardiac and dynamic arterial CT.

Authors:  Michael Bindschadler; Kelley R Branch; Adam M Alessio
Journal:  Phys Med Biol       Date:  2018-05-21       Impact factor: 3.609

2.  Sex differences in calcified plaque and long-term cardiovascular mortality: observations from the CAC Consortium.

Authors:  Leslee J Shaw; James K Min; Khurram Nasir; Joe X Xie; Daniel S Berman; Michael D Miedema; Seamus P Whelton; Zeina A Dardari; Alan Rozanski; John Rumberger; C Noel Bairey Merz; Mouaz H Al-Mallah; Matthew J Budoff; Michael J Blaha
Journal:  Eur Heart J       Date:  2018-11-01       Impact factor: 29.983

3.  A need to reduce premature CV mortality in the developing world: How could appropriate use of non-invasive imaging help?

Authors:  João V Vitola
Journal:  J Nucl Cardiol       Date:  2018-11-20       Impact factor: 5.952

4.  Myocardial perfusion imaging in women for the evaluation of stable ischemic heart disease-state-of-the-evidence and clinical recommendations.

Authors:  Viviany R Taqueti; Sharmila Dorbala; David Wolinsky; Brian Abbott; Gary V Heller; Timothy M Bateman; Jennifer H Mieres; Lawrence M Phillips; Nanette K Wenger; Leslee J Shaw
Journal:  J Nucl Cardiol       Date:  2017-06-05       Impact factor: 5.952

5.  Combined non-invasive imaging for predicting cardiovascular events : Is three a crowd?

Authors:  Austin A Robinson; Jamieson M Bourque
Journal:  J Nucl Cardiol       Date:  2016-11-09       Impact factor: 5.952

Review 6.  Implementation of Cholesterol-Lowering Therapy to Reduce Cardiovascular Risk in Persons Living with HIV.

Authors:  Stephani C Wang; Gurleen Kaur; Joshua Schulman-Marcus; Scott Purga; Sulagna Mookherjee; Cyndi Miller; Mandeep S Sidhu; Robert S Rosenson
Journal:  Cardiovasc Drugs Ther       Date:  2020-09-26       Impact factor: 3.727

Review 7.  Coronary Computed Tomography Angiography: Enhancing Risk Stratification and Diagnosis of Cardiovascular Disease in Women.

Authors:  Sara Karnib; Kavitha M Chinnaiyan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-10-04

8.  Update of the Brazilian Guideline on Nuclear Cardiology - 2020.

Authors:  Luiz Eduardo Mastrocola; Barbara Juarez Amorim; João Vicente Vitola; Simone Cristina Soares Brandão; Gabriel Blacher Grossman; Ronaldo de Souza Leão Lima; Rafael Willain Lopes; William Azem Chalela; Lara Cristiane Terra Ferreira Carreira; José Roberto Nolasco de Araújo; Cláudio Tinoco Mesquita; José Claudio Meneghetti
Journal:  Arq Bras Cardiol       Date:  2020-02       Impact factor: 2.000

9.  Machine learning integration of circulating and imaging biomarkers for explainable patient-specific prediction of cardiac events: A prospective study.

Authors:  Balaji K Tamarappoo; Andrew Lin; Frederic Commandeur; Priscilla A McElhinney; Sebastien Cadet; Markus Goeller; Aryabod Razipour; Xi Chen; Heidi Gransar; Stephanie Cantu; Robert Jh Miller; Stephan Achenbach; John Friedman; Sean Hayes; Louise Thomson; Nathan D Wong; Alan Rozanski; Piotr J Slomka; Daniel S Berman; Damini Dey
Journal:  Atherosclerosis       Date:  2020-11-13       Impact factor: 5.162

10.  Semiquantitative score of breast arterial calcifications on mammography (BAC-SS): intra- and inter-reader reproducibility.

Authors:  Rubina Manuela Trimboli; Marina Codari; Andrea Cozzi; Caterina Beatrice Monti; Davide Capra; Carolina Nenna; Diana Spinelli; Giovanni Di Leo; Giuseppe Baselli; Francesco Sardanelli
Journal:  Quant Imaging Med Surg       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.